ERBB2 and breast cancer: It has been reported that overexpression of WNT3 activates the Wnt/β-catenin signaling pathway, resulting in transactivation of EGFR and provoking an EMT-like phenotype, which in turn could underlie the trastuzumab resistance of HER2+ breast cancers [36].